The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino wistar rats

European Review for Medical and Pharmacological Sciences

Volumn 13, Issue 6, 2009, Pages 443-451

  El Gawly, Hoda W ^a   Tawfik, Mona K ^a   Rashwan, Maha F ^a   Baruzaig, Ali S ^a  

^a Suez Canal University Faculty of Medicine   (Egypt)

Author keywords

Experimental diabetes; Pioglitazone and hepatotoxicity; Thiazolidinediones (TZDs)

Indexed keywords

BUFFER; CITRIC ACID; GLUCOSE; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INFLAMMATORY INFILTRATE; LIVER; LIVER NECROSIS; LIVER TOXICITY; LYMPHOCYTIC INFILTRATION; MALE; MICROSCOPY; NONHUMAN; RAT; SEROLOGY; SINGLE DRUG DOSE; STOMACH TUBE; STREPTOZOCIN DIABETES; TREATMENT RESPONSE; WISTAR ALBINO GLAXO RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; HYPOGLYCEMIC AGENTS; LIVER; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 74949131319     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. WINER N, SOWERS JR. Epidemiology of diabetes. J Clin Pharmacol 2004; 44: 397-405.
2. WILD S, ROGLIC G, GREEN A, SICREE R, KING H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
3. INTERNATIONAL DIABETES FEDERATION. Diabetes Atlas. 3rd ed. Brussels; International Diabetes Federation, 2006.
4. TUOMILEHTO J, RASTENYTE D, QIAO Q, JAKOVLJEVIC D. Epidemiology of macrovascular disease and hypertension in diabetes mellitus. In: De Fronzo RA, Ferrannini E, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus, 3rd edn. John Wiley & Sons, Milan, 2004, pp 1345-1370.
5. TOLMAN K, FONSECA V, DALPIAZ A, TAN MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care 2007; 30: 734-743.
6. DE FRONZO RA, FERRANNINI E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.
7. XU P, ZHANG XG, LI YM, YU CH, XU L, XU GY. Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease (NAFLD) in rats. J Zhejiang Univ Sci B 2006; 7: 627-633.
8. ALBERTI KG, ZIMMET P, SHAW J. Metabolic syndrome. Diabet Med 2006; 23: 469-480.
9. CHEN J, MUNTNER P, HAMM LL, JONES DW, BATUMAN V, FONSECA V, WHELTON PK, HE J. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174.
10. JOHANSEN OE, JØRGENSEN AP. Glitazone treatment of type 2 diabetes mellitus. Tidsskr Nor Laegeforen 2006; 126: 1928-1930.
11. SARAFIDIS PA, LASARIDIS AN. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006; 19: 646-653.
12. ARODA V, HINRY R. Thiazolidinediones: potential link between insulin resistance and cardiovascular disease. Diabetes Spectrum 2003; 16: 120-125.
13. ANDRADE RJ, LUCENA MI, FERNÁNDEZ MC, PELAEZ G, PACHKORIA K, GARCÍA-RUIZ E, GARCÍA-MUÑOZ B, GONZÁLEZ- GRANDE R, PIZARRO A, DURÁN JA, JIMÉNEZ M, RODRIGO L, ROMERO-GOMEZ M, NAVARRO JM, PLANAS R, COSTA J, BORRAS A, SOLER A, SALMERÓN J, MARTIN-VIVALDI R; SPANISH GROUP FOR THE STUDY OF DRUG-INDUCED LIVER DISEASE. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-521.
14. KAWAMORI R, KADOWAKI T, ONJI M, SEINO Y, AKANUMA Y. PRACTICAL (PRospective ACTos practICAL experience) Study: Updated Efficacy and Safety in 23,000 Japanese Type 2 Diabetes Patients, in: 65th American Diabetes Association, June, San Diego, California 2005; pp 10-14.
15. LEBOVITZ HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002; 18: S23-S29.
16. LEBOVITZ HE, KREIDER M, FREED MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-821.
17. MENEES SB, ANDERSON MA, CHENSUE SW, MOSELEY RH. Hepatic injury in a patient taking rosiglitazone. J Clin Gastroenterol 2005; 39: 638-640.
18. SNOW KL, MOSELEY RH. Effect of thiazolidinediones on bile acid transport in rat liver. Life Sci 2007; 80: 732-740.
19. AL-SALMAN J, ARJOMAND H, KEMP DG, MITTAL M. Hepatocellular injury in a patient receiving rosiglitazone: a case report. Ann Intern Med 2000; 132: 121-124.
20. MAY LE, LEFKOWITCH JH, KRAM MT, RUBIN DE. Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann Intern Med 2002; 136: 449-452.
21. Rubin CJ, Schneider RL. Pioglitazone liver enzyme profile is similar to placebo in U.S. controlled clinical trials. Diabetes 2000; 49(Suppl. 1): A123.
22. Belcher G, Schernthaner G. Changes in liver tests during 1-year treatment of patients with Type 2 diabetes with pioglitazone, metformin or gliclazide. Diabet Med 2005; 22: 973-979.
23. MCCULLOUGH AJ. Thiazolidinediones for nonalcoholic steatohepatitis, promising but not ready for prime time. N Engl J Med 2006; 355: 2361-2363.
24. KAWAMORI R, KADOWAKI T, ONJI M, SEINO Y, AKANUMA Y. Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus: Postmarketing surveillance study in Japan. Diabetes Res Clin Pract 2007; 76: 229-235.
25. SCHEEN AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001; 24: 873-888.
26. PARRA RS, MENDES LA, FAZAN R JR, SALGADO HC. Pressure response to carotid occlusion in diabetic rats: effect of insulin therapy. Diabetes Res Clin Pract 2005; 68: 12-17.
27. SINGH J, BUDHIRAJA S, LAL H, ARORA BR. Renoprotection by telmisartan versus benazepril in streptozotocin induced diabetic nephropathy. Iranian J Pharmacol Ther (UPT) 2006; 5: 135-139.
28. BANCROFT JD, STEVENS A. Staining techniques. In: Theory and practice of histological techniques. 3rd ed. Churcill Livingstone, 1990.
29. JALVING M, DE JONG S, KOORNSTRA J J, BOERSMA-VAN EK W, ZWART N, WESSELING J, DE VRIES EGE AND KLEIBEUKER JH. TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res 2006; 12: 4350-4356.
30. DRACHENBERG CB, LOFFE OB, PAPADIMITRIOU JC. Progressive increase of apoptosis in prostatic intraepithelial neoplasia and carcinoma: comparison between in situ end-labeling of fragmented DNA and detection by routine hematoxylineosin staining. Arch Pathol Lab Med 1997; 121: 54-58.
31. NATIONAL DIABETES INFORMATION CLEARINGHOUSE (NDIC). National diabetes statistics, 2008. http://diabetes.niddk.nih.gov/dm/pubs/statistics/index.htm#7.
32. VAGULA M, DEVI SS. Hepatotoxicity of antidiabetic drugs. US Pharm. 2008; 33: 3-9.
33. CHEN H, REN A, HU S, MO W, XIN X, JIA W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Res Clin Pract 2007; 75: 327-332.
34. EUROPEAN MEDICINES AGENCY (EMEA). (2008); Non-clinical guideline on drug-induced hepatotoxicity.
35. MAEDA K. Hepatocellular injury in a patient receiving pioglitazone. Ann Intern Med 2002; 135: 306.
36. CHASE MP, YARZE JC. Pioglitazone-associated fulminant hepatic failure. Am J Gastroenterol 2002; 97: 502-503.
37. EL-SERAG HB, EVERHART JE. Diabetes increases the risk of acute hepatic failure. Gastroenterology 2002; 122: 1822-1828.
38. VUPPALANCHI R, TEAL E, CHALASANI N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. Am J Med Sci 2005; 329: 62-65.
39. WATKINS PB, SEEFF LB. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 2006; 43: 618-631.
40. REUBEN A. Hy's law. Hepatology 2004; 39: 574-578.
41. ??AKBARZADEH A, NOROUZIAN D, MEHRABI MR, JAMSHIDI SH, FARHANGI A, ALLAH VERDI A, MOFIDIAN1 SMA LAME RAD B. Induction of diabetes by streptozotocin in rats. Indian J Clin Biochem 2007; 22: 60-64.
42. CARNOVALE CE, RODRIGUEZ GARAY EA. Reversible impairment of hepatobiliary function induced by streptozotocin in the rat. Experientia 1984; 40: 248-250.
43. NOORAFSHAN A, ESMAIL-ZADEH B, BAHMANPOUR S, POOST-PASAND A. Early stereological changes in liver of Sprague-Dawley rats after streptozotocin injection. Indian J Gastroenterol 2005; 24: 104-107.
44. GASTALDELLI A, MIYAZAKI Y, MAHANKALI A, BERRIA R, PETTITI M, BUZZIGOU E, FERRANNINI E, DEFRONZO RA. The Effect of pioglitazone on the liver: role of adiponectin. Diabetes Care 2006; 29: 2275-2281.
45. RAJAGOPALAN R, IYER S, PEREZ A. Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: no evidence of increased risk of liver failure with pioglitazone. Diabetes Obes Metab 2005; 7: 161-169.
46. TARGHER G, BERTOLINI L, POLI F, RODELLA S, SCALA L, TESSARI R, ZENARI L, FALEZZA G. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-3546.
47. BAJAJ M, SURAAMORNKUL S, PIPER P, HARDIES LJ, GLASS L, CERSOSIMO E, PRATIPANAWATR T, MIYAZAKI Y, DEFRONZO RA. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 2004; 89: 200-206.
48. HOME PD, PACINI G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes Obes Metab 2008; 10: 699-718.
49. EL-SERAG HB, TRAN T, EVERHART JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468.
50. YUAN GJ, ZHANG ML, GONG ZJ. Effects of PPARγ agonist pioglitazone on rat hepatic fibrosis. World J Gastroenterol 2004; 10: 1047-1051.
51. DORMANDY JA, CHARBONNEL B, ECKLAND DJ, ERDMANN E, MASSI-BENEDETTI M, MOULES IK, SKENE AM, TAN MH, LEFÈBVRE PJ, MURRAY GD, STANDL E, WILCOX RG, WILHELMSEN L, BETTERIDGE J, BIRKELAND K, GOLAY A, HEINE RJ, KORÁNYI L, LAAKSO M, MOKÁN M, NORKUS A, PIRAGS V, PODAR T, SCHEEN A, SCHERBAUM W, SCHERNTHANER G, SCHMITZ O, SKRHA J, SMITH U, TATON J; PROACTIVE INVESTIGATORS. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
52. BAJAJ M, SURAAMORNKUL S, PRATIPANAWATR T, HARDIES LJ, PRATIPANAWATR W, GLASS L, CERSOSIMO E, MIYAZAKI Y, DEFRONZO RA. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52: 1364-1370.
53. NEUSCHWANDER-TETRI BA, CALDWELL SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
54. GUMIENICZEK A. Effect of the new thiazolidinedionepioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 2003; 74: 553-562.
55. PLUTZKY J, VIBERTI G, HAFFNER S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 2002; 16: 401-415.